The safest drug that no one can afford or that arrives too late is of no benefit to a patient. How much evidence is needed? When is the right time for access? Who should receive it? This ‘access-evidence conundrum’ is one of the key challenges facing healthcare decision-making. Join us for a conversation with experts from the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), payers, patient advocates and industry to discuss potential ways forward to improve timely patient access, drawing on best practices from both sides of the Atlantic.

Panel speakers include:

Dr Sandra Kweder

Deputy Director, Europe Office

FDA and FDA Liaison to the EMA

Jo De Cock

Director General,

INAMI-RIZIV (Belgian National Institute for Health and Disability Insurance)

Dr Lydia Makaroff

Director,

European Cancer Patient Coalition

Martin Strandberg-Larsen

Vice-President Market Access and Pricing

Nordic – Baltic Marketing Company

AstraZeneca

EMA representative (to be confirmed)

Moderated by Alexander Roediger, Chair, AmCham EU Healthcare Committee and Policy Lead

Oncology, EMEAC, MSD Europe

Additional speakers and programme to be announced shortly.